Baoli Pharmaceutical

Baoli (Beijing) Pharmaceutical Technology is a clinical-stage biotechnology company based in Beijing, China, focused on the discovery and development of innovative small molecule drugs for oncology and immunology. The company's research platform centers on modulating the innate immune system, particularly through the development of Toll-like receptor (TLR) agonists. Its lead candidate, BL-01, is a potent TLR7 agonist designed to enhance anti-tumor immune responses and is currently being evaluated in Phase 1 clinical trials for various solid tumors. Baoli Pharmaceutical aims to address unmet medical needs in cancer therapy by combining its proprietary R&D capabilities with strategic collaborations. The company was founded by Dr. Li Baoli and leverages deep expertise in medicinal chemistry to create next-generation immunotherapies.